148 related articles for article (PubMed ID: 8998275)
1. Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs.
Maes M; Bosmans E; Ranjan R; Vandoolaeghe E; Meltzer HY; De Ley M; Berghmans R; Stans G; Desnyder R
Schizophr Res; 1996 Jul; 21(1):39-50. PubMed ID: 8998275
[TBL] [Abstract][Full Text] [Related]
2. In vivo immunomodulatory effects of clozapine in schizophrenia.
Maes M; Bosmans E; Kenis G; De Jong R; Smith RS; Meltzer HY
Schizophr Res; 1997 Aug; 26(2-3):221-5. PubMed ID: 9323354
[TBL] [Abstract][Full Text] [Related]
3. Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics.
Maes M; Bocchio Chiavetto L; Bignotti S; Battisa Tura G; Pioli R; Boin F; Kenis G; Bosmans E; de Jongh R; Lin A; Racagni G; Altamura CA
Eur Neuropsychopharmacol; 2000 Mar; 10(2):119-24. PubMed ID: 10706993
[TBL] [Abstract][Full Text] [Related]
4. Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in posttraumatic stress disorder following accidental man-made traumatic events.
Maes M; Lin AH; Delmeire L; Van Gastel A; Kenis G; De Jongh R; Bosmans E
Biol Psychiatry; 1999 Apr; 45(7):833-9. PubMed ID: 10202570
[TBL] [Abstract][Full Text] [Related]
5. Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment.
Erbağci AB; Herken H; Köylüoglu O; Yilmaz N; Tarakçioglu M
Mediators Inflamm; 2001 Jun; 10(3):109-15. PubMed ID: 11545247
[TBL] [Abstract][Full Text] [Related]
6. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6.
Lin A; Kenis G; Bignotti S; Tura GJ; De Jong R; Bosmans E; Pioli R; Altamura C; Scharpé S; Maes M
Schizophr Res; 1998 Jun; 32(1):9-15. PubMed ID: 9690329
[TBL] [Abstract][Full Text] [Related]
7. Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients.
Sirota P; Meiman M; Herschko R; Bessler H
Psychiatry Res; 2005 Apr; 134(2):151-9. PubMed ID: 15840416
[TBL] [Abstract][Full Text] [Related]
8. Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders.
Igue R; Potvin S; Bah R; Stip E; Bouchard RH; Lipp O; Gendron A; Kouassi E
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1695-8. PubMed ID: 21627977
[TBL] [Abstract][Full Text] [Related]
9. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine.
Maes M; Meltzer HY; Bosmans E
Acta Psychiatr Scand; 1994 May; 89(5):346-51. PubMed ID: 8067274
[TBL] [Abstract][Full Text] [Related]
10. Serotonin-immune interactions in detoxified chronic alcoholic patients without apparent liver disease: activation of the inflammatory response system and lower plasma total tryptophan.
Maes M; Lin A; Bosmans E; Vandoolaeghe E; Bonaccorso S; Kenis G; De Jongh R; Verkerk R; Song C; Scharpé S; Neels H
Psychiatry Res; 1998 May; 78(3):151-61. PubMed ID: 9657419
[TBL] [Abstract][Full Text] [Related]
11. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor.
Maes M; Bocchio Chiavetto L; Bignotti S; Battisa Tura GJ; Pioli R; Boin F; Kenis G; Bosmans E; de Jongh R; Altamura CA
Schizophr Res; 2002 Apr; 54(3):281-91. PubMed ID: 11950553
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers.
Maes M; Bosmans E; Calabrese J; Smith R; Meltzer HY
J Psychiatr Res; 1995; 29(2):141-52. PubMed ID: 7666381
[TBL] [Abstract][Full Text] [Related]
13. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia.
Zhang XY; Zhou DF; Cao LY; Zhang PY; Wu GY; Shen YC
J Clin Psychiatry; 2004 Jul; 65(7):940-7. PubMed ID: 15291683
[TBL] [Abstract][Full Text] [Related]
14. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression.
Maes M; Bosmans E; De Jongh R; Kenis G; Vandoolaeghe E; Neels H
Cytokine; 1997 Nov; 9(11):853-8. PubMed ID: 9367546
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration.
Akiyama K
Schizophr Res; 1999 May; 37(1):97-106. PubMed ID: 10227112
[TBL] [Abstract][Full Text] [Related]
16. Immunological differences between patients with major depression and somatization syndrome.
Rief W; Pilger F; Ihle D; Bosmans E; Egyed B; Maes M
Psychiatry Res; 2001 Dec; 105(3):165-74. PubMed ID: 11814536
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-1 receptor antagonists and other markers in colorectal cancer patients.
Iwagaki H; Hizuta A; Tanaka N
Scand J Gastroenterol; 1997 Jun; 32(6):577-81. PubMed ID: 9200291
[TBL] [Abstract][Full Text] [Related]
18. Clara cell secretory protein (CC16) gene polymorphism and schizophrenia in humans.
Hori H; Ohmori O; Shinkai T; Kojima H; Nakamura J
Neurosci Lett; 2001 Jan; 298(1):75-7. PubMed ID: 11154839
[TBL] [Abstract][Full Text] [Related]
19. Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia.
Rapaport MH; Lohr JB
Acta Psychiatr Scand; 1994 Nov; 90(5):311-5. PubMed ID: 7872033
[TBL] [Abstract][Full Text] [Related]
20. COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy.
Müller N; Ulmschneider M; Scheppach C; Schwarz MJ; Ackenheil M; Möller HJ; Gruber R; Riedel M
Eur Arch Psychiatry Clin Neurosci; 2004 Feb; 254(1):14-22. PubMed ID: 14991374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
